Trial Profile
A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Letermovir (Primary) ; Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Proof of concept; Therapeutic Use
- 28 Mar 2022 Status changed from recruiting to completed.
- 07 Feb 2022 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 07 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Mar 2022.